The market is indifferent to today's 79th partnership because there is no indication of financial terms or ETA for any product that will ultimately produce not just royalty payment's, but ingredient sales and distribution agreements. Nevertheless, what is important is the increasing USA/Canadian presence that will be needed for any proposed North American listing, I presume to be NASDAQ. Any such IPO on an important exchange will need a good presence to attract the excitement of institutions and retail investors alike. Let us not forget, this also leverages the trademark and IP as the ''intel inside'' go-to probiotic. ProBiotix Limited LP-LDL Not only has FDA GMP pharma or GRAS and together is a significant differential and in my view is the future of the industry. This opens up opportunities in pharma above and beyond the existing deals we have in place.
The company makes greens+, omegas, proteins and probiotics. Genuine Health’s greens+ is the #1 superfood in Canada and the only superfood to be validated by nine clinical studies as reported on their website. The Genuine Health website also states that it specialises in natural, science-based, clinically proven products with ingredients which create product differentiation in the North American market. As part of the agreement, Genuine Health will submit products containing LPLDL® for cardiovascular and other health claims to Health Canada, a department of the Government of Canada responsible for the country’s federal health policy.
The Company believes that if registration is successful, LPLDL® will be the first probiotic supplement in the Canadian market to obtain a specific health claim for cardiovascular health. This agreement is another step in building brand and product presence in the large North American market as a dietary supplement, a live biotherapeutic product (LBP), or a functional ingredient. The agreement is for an initial period of 36 months.
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health, commented: “We are pleased to have signed an agreement with Genuine Health in such a large and important market for probiotic products. We believe working with Genuine Health creates a unique opportunity to achieve a probiotic health claim for cardiovascular health and provide further product differentiation in the North American market. We see this as another step in building revenues and market presence of LPLDL® inside a wide range of products, presented in different presentations and formulations, for cardiovascular health in both consumer and pharmaceutical markets around the world.”
Stewart Brown, Founder and CEO of at Genuine Health, commented: “We are excited to work towards introducing innovative and science-backed products into the North American market through our relationship with ProBiotix. The ProBiotix team continue to produce cutting edge research surrounding the link between probiotics (LPLDL®) and cardiovascular health. This makes them a great partner in our mission to create products that promote whole-body health and wellness, with a particular focus on the powerful role of the microbiome. We look forward to a long and successful partnership with ProBiotix Health.”